Literature DB >> 10672236

Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases.

M P Mattson1, W A Pedersen, W Duan, C Culmsee, S Camandola.   

Abstract

Synaptic degeneration and death of nerve cells are defining features of Alzheimer's disease (AD) and Parkinson's disease (PD), the two most prevalent age-related neurodegenerative disorders. In AD, neurons in the hippocampus and basal forebrain (brain regions that subserve learning and memory functions) are selectively vulnerable. In PD dopamine-producing neurons in the substantia nigra-striatum (brain regions that control body movements) selectively degenerate. Studies of postmortem brain tissue from AD and PD patients have provided evidence for increased levels of oxidative stress, mitochondrial dysfunction and impaired glucose uptake in vulnerable neuronal populations. Studies of animal and cell culture models of AD and PD suggest that increased levels of oxidative stress (membrane lipid peroxidation, in particular) may disrupt neuronal energy metabolism and ion homeostasis, by impairing the function of membrane ion-motive ATPases and glucose and glutamate transporters. Such oxidative and metabolic compromise may there-by render neurons vulnerable to excitotoxicity and apoptosis. Studies of the pathogenic mechanisms of AD-linked mutations in amyloid precursor protein (APP) and presenilins strongly support central roles for perturbed cellular calcium homeostasis and aberrant proteolytic processing of APP as pivotal events that lead to metabolic compromise in neurons. Specific molecular "players" in the neurodegenerative processes in AD and PD are being identified and include Par-4 and caspases (bad guys) and neurotrophic factors and stress proteins (good guys). Interestingly, while studies continue to elucidate cellular and molecular events occurring in the brain in AD and PD, recent data suggest that both AD and PD can manifest systemic alterations in energy metabolism (e.g., increased insulin resistance and dysregulation of glucose metabolism). Emerging evidence that dietary restriction can forestall the development of AD and PD is consistent with a major "metabolic" component to these disorders, and provides optimism that these devastating brain disorders of aging may be largely preventable.

Entities:  

Mesh:

Year:  1999        PMID: 10672236     DOI: 10.1111/j.1749-6632.1999.tb07824.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  99 in total

1.  Direct cleavage of AMPA receptor subunit GluR1 and suppression of AMPA currents by caspase-3: implications for synaptic plasticity and excitotoxic neuronal death.

Authors:  Chengbiao Lu; Weiming Fu; Guy S Salvesen; Mark P Mattson
Journal:  Neuromolecular Med       Date:  2002       Impact factor: 3.843

Review 2.  Do apoptotic mechanisms regulate synaptic plasticity and growth-cone motility?

Authors:  Charles P Gilman; Mark P Mattson
Journal:  Neuromolecular Med       Date:  2002       Impact factor: 3.843

3.  Aging-related gene expression in hippocampus proper compared with dentate gyrus is selectively associated with metabolic syndrome variables in rhesus monkeys.

Authors:  Eric M Blalock; Richard Grondin; Kuey-chu Chen; Olivier Thibault; Veronique Thibault; Jignesh D Pandya; Amy Dowling; Zhiming Zhang; Patrick Sullivan; Nada M Porter; Philip W Landfield
Journal:  J Neurosci       Date:  2010-04-28       Impact factor: 6.167

Review 4.  Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections.

Authors:  Wojciech Danysz; Chris G Parsons
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

Review 5.  Glutamate and neurotrophic factors in neuronal plasticity and disease.

Authors:  Mark P Mattson
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

6.  Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway.

Authors:  Hoon Ryu; Junghee Lee; Beatrix A Olofsson; Aziza Mwidau; Alpaslan Dedeoglu; Maria Escudero; Erik Flemington; Jane Azizkhan-Clifford; Robert J Ferrante; Rajiv R Ratan; Alpaslan Deodoglu
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-14       Impact factor: 11.205

Review 7.  Mitochondrial Dysfunction and Synaptic Transmission Failure in Alzheimer's Disease.

Authors:  Lan Guo; Jing Tian; Heng Du
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

8.  Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model: potential use as an adjuvant treatment in Parkinson's disease.

Authors:  Marianna Sikorska; Patricia Lanthier; Harvey Miller; Melissa Beyers; Caroline Sodja; Bogdan Zurakowski; Sandhya Gangaraju; Siyaram Pandey; Jagdeep K Sandhu
Journal:  Neurobiol Aging       Date:  2014-04-02       Impact factor: 4.673

Review 9.  Brain metabolism in health, aging, and neurodegeneration.

Authors:  Simonetta Camandola; Mark P Mattson
Journal:  EMBO J       Date:  2017-04-24       Impact factor: 11.598

10.  Cytoplasmic p53 and activated Bax regulate p53-dependent, transcription-independent neural precursor cell apoptosis.

Authors:  Ying Geng; K C Walls; Arindam P Ghosh; Rizwan S Akhtar; Barbara J Klocke; Kevin A Roth
Journal:  J Histochem Cytochem       Date:  2009-11-09       Impact factor: 2.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.